Reveal Pharma
Monday, June 03, 2024
Oncology
Company Presentation Theater 1
Reveal is transforming medical insight with the first gadolinium-free general purpose MRI contrast agent RVP-001 (Phase 2 clinical studies) and fibrogenesis-targeted imaging agents (pre-clinical). Our imaging agents are based on technology invented at the Caravan Lab at Harvard Medical School and have broad potential applicability to many disease indications from oncology through CNS to fibrotic diseases for diagnosis, patient management, and study read out.
Company Website:
http://www.revealpharma.com
Lead Product in Development:
RVP-001 - manganese-based general purpose MRI contrast agent
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Cambridge
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
Vera Hoffman
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())